Rinucumab
Based on 1 Customer Validation
Rinucumab (REGN2176) is an anti-PDGFR-β antibody. Rinucumab is used for research on neovascular age-related macular degeneration.
For research use only. We do not sell to patients.
- Purity : 99.9%
- CAS No.: 1569263-06-4
- Molecular Weight:145.5 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
PDGFR-β |
In Vitro
Rinucumab can be used in combination with Aflibercept (HY-108801) for vision research[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID
Accession
NP_002600.1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized PDGF-BB Protein, Human can bind Rinucumab. The EC50 for this effect is 10.71 ng/mL. -
Chemical Information
-
CAS No. 1569263-06-4
-
Appearance Liquid
-
Molecular Weight 145.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Rinucumab]
-
Synonyms
REGN2176
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Dunn EN, et al. An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. Ophthalmic Surg Lasers Imaging Retina. 2017 Feb 1;48(2):100-104. [Content Brief]
[2]. Megan Cully, et al. Deal watch: Novartis eyes vision-enhancing therapy for macular degeneration. Nat Rev Drug Discov. 2014 Jul;13(7):487. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)